Insulin Secretion Stimulants Overview
50 Questions
2 Views

Insulin Secretion Stimulants Overview

Created by
@SufficientBohrium

Questions and Answers

Which drug class includes agents that stimulate insulin secretion?

  • GLP-1 Analogues
  • Sulfonylureas (correct)
  • Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
  • Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors
  • Which of the following is NOT a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor?

  • Saxagliptin
  • Sitagliptin
  • Repaglutide (correct)
  • Linagliptin
  • Which insulin sensitivity-increasing drug is derived from the biguanide class?

  • Dapagliflozin
  • Metformin (correct)
  • Pioglitazone
  • Glyburide
  • Which of the following is an Amylin analogue?

    <p>Pramlintide</p> Signup and view all the answers

    Which drugs are classified as Thionamides?

    <p>Methimazole and Propylthiouracil</p> Signup and view all the answers

    Which of the following are classified as GLP-1 Analogues?

    <p>Liraglutide</p> Signup and view all the answers

    Which choice includes only Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors?

    <p>Canagliflozin, Dapagliflozin, Empagliflozin</p> Signup and view all the answers

    Which of the following drugs is a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor?

    <p>Sitagliptin</p> Signup and view all the answers

    Which of the following pairs correctly matches a class of drugs with its specific agent?

    <p>Thionamides - Methimazole</p> Signup and view all the answers

    Which drugs serve as Amylin Analogues?

    <p>Pramlintide</p> Signup and view all the answers

    Which of the following agents is a Thionamide used for medical management?

    <p>Methimazole</p> Signup and view all the answers

    Identify the agent that falls under the category of Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors.

    <p>Empagliflozin</p> Signup and view all the answers

    Which of the following drugs is NOT a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor?

    <p>Repaglinide</p> Signup and view all the answers

    Which drug is classified as a GLP-1 analogue?

    <p>Liraglutide</p> Signup and view all the answers

    Which of the following medications is a drug that increases insulin sensitivity?

    <p>Metformin</p> Signup and view all the answers

    Which medication is a member of the 2nd generation Sulfonylureas?

    <p>Glipizide</p> Signup and view all the answers

    What is the primary action of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors?

    <p>Inhibit incretin degradation</p> Signup and view all the answers

    Which of the following is NOT classified as a Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitor?

    <p>Metformin</p> Signup and view all the answers

    Which of the following medications acts as a dopamine agonist?

    <p>Bromocriptine</p> Signup and view all the answers

    Which of these options contains only Amylin Analogues?

    <p>Pramlintide, Exenatide</p> Signup and view all the answers

    Which of the following drugs is a 1st generation Sulfonylurea?

    <p>Chlorpropamide</p> Signup and view all the answers

    Which of the following drug classes includes agents that improve insulin sensitivity?

    <p>Drugs which Increase Insulin Sensitivity</p> Signup and view all the answers

    Which medication is classified under Dopamine Agonists?

    <p>Cabergoline</p> Signup and view all the answers

    Which two medications are examples of SGLT2 Inhibitors?

    <p>Canagliflozin, Empagliflozin</p> Signup and view all the answers

    What class of drugs does Fludrocortisone belong to?

    <p>Aldosterone Analogues</p> Signup and view all the answers

    Which of the following drugs is an example of a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor?

    <p>Saxagliptin</p> Signup and view all the answers

    Which class of drugs does Bromocriptine belong to?

    <p>Dopamine Agonists</p> Signup and view all the answers

    What is the primary therapeutic target of Alpha-Glucosidase Inhibitors?

    <p>Inhibit glucose absorption</p> Signup and view all the answers

    Which of the following medications increases insulin sensitivity?

    <p>Metformin</p> Signup and view all the answers

    Which medication is classified as a Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitor?

    <p>Dapagliflozin</p> Signup and view all the answers

    Which of the following medications is also known as a GLP-1 analogue?

    <p>Liraglutide</p> Signup and view all the answers

    Which agent is classified as a Dipeptidyl Peptidase-4 (DPP-4) inhibitor?

    <p>Saxagliptin</p> Signup and view all the answers

    Which of the following is primarily used to increase insulin sensitivity?

    <p>Pioglitazone</p> Signup and view all the answers

    Which of the following agents is a sodium-glucose co-transporter 2 (SGLT2) inhibitor?

    <p>Dapagliflozin</p> Signup and view all the answers

    Which of the following is an example of a Thionamide?

    <p>Propylthiouracil</p> Signup and view all the answers

    What is a noted characteristic of Sulfonylureas in relation to insulin secretion?

    <p>They stimulate insulin secretion from the pancreas.</p> Signup and view all the answers

    Which of the following classes of drugs primarily increase insulin sensitivity?

    <p>Drugs which Increase Insulin Sensitivity</p> Signup and view all the answers

    Which agent is included in the class of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors?

    <p>Linagliptin</p> Signup and view all the answers

    What type of medication is Pramlintide classified as?

    <p>Amylin Analogue</p> Signup and view all the answers

    Which medication from the provided list is a member of the class of Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors?

    <p>Empagliflozin</p> Signup and view all the answers

    Which drug class is primarily associated with the medications Nateglinide and Repaglinide?

    <p>Meglitinides</p> Signup and view all the answers

    What is the mechanism of action for Dipeptidyl Peptidase-4 (DPP-4) Inhibitors?

    <p>Enhance incretin levels</p> Signup and view all the answers

    Which of the following medications is an example of an Aldosterone analogue?

    <p>Fludrocortisone</p> Signup and view all the answers

    Which medication listed is associated with increasing insulin sensitivity?

    <p>Metformin</p> Signup and view all the answers

    Which of the following is NOT classified as a Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitor?

    <p>Sitagliptin</p> Signup and view all the answers

    Which medication is specifically recognized as a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor?

    <p>Saxagliptin</p> Signup and view all the answers

    Which drug class includes Glipizide as a member?

    <p>Sulfonylureas</p> Signup and view all the answers

    What is the primary therapeutic action of Metformin?

    <p>Enhance insulin sensitivity</p> Signup and view all the answers

    Which medication serves as an Amylin analogue?

    <p>Pramlintide</p> Signup and view all the answers

    Which of the following agents is NOT classified under the category of Sulfonylureas?

    <p>Repaglinide</p> Signup and view all the answers

    Study Notes

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Insulin Secretion Stimulants

    • Sulfonylureas: Drugs that stimulate insulin secretion from pancreatic beta cells.
      • 1st Generation:
        • Chlorpropamide: First sulfonylurea, longer-acting, risk of hypoglycemia.
        • Tolbutamide: Shorter duration, less effective in long-term use.
      • 2nd Generation:
        • Glipizide: Rapid action, commonly prescribed for type 2 diabetes.
        • Glyburide: Potent in insulin secretion stimulation, moderate hypoglycemia risk.
      • Meglitinides: Promote insulin release, more targeted and shorter effects.
      • 3rd Generation:
        • Nateglinide: Quick onset, taken before meals to manage blood sugar spikes.
        • Repaglinide: Similar to nateglinide, effective in postprandial glucose control.

    GLP-1 Analogues

    • Mimic the incretin hormone GLP-1, enhance insulin secretion, slow gastric emptying.
      • Exenatide: First GLP-1 analogue, improves glycemic control.
      • Liraglutide: Once daily injection, weight loss benefits.
      • Semaglutide: Weekly injection, significant weight loss and glycemic improvements.

    Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    • Inhibit DPP-4 enzyme, prolonging incretin levels and enhancing insulin secretion.
      • Linagliptin: No renal adjustment, well-tolerated.
      • Saxagliptin: Moderate renal function adjustments required.
      • Sitagliptin: Commonly used, effective in lowering blood sugar levels.

    Sodium - Glucose Co-Transporter 2 (SGLT2) Inhibitors

    • Block reabsorption of glucose in kidneys, promoting its excretion.
      • Canagliflozin: Associated with improved cardiovascular outcomes.
      • Dapagliflozin: Reduces risk of heart failure hospitalization.
      • Empagliflozin: Helps prevent cardiovascular events in high-risk patients.

    Alpha-Glucosidase Inhibitors

    • Delay carbohydrate absorption from the intestines.
      • Acarbose: Works in the intestine, minimizing postprandial glucose spikes.
      • Miglitol: Similar mechanism, effective in managing type 2 diabetes.

    Amylin Analogues

    • Pramlintide: Synthetic analogue of amylin, regulates postprandial blood sugar levels.

    Thionamides

    • Inhibit thyroid hormone synthesis, used in hyperthyroidism management.
      • Methimazole: Preferred due to fewer side effects.
      • Propylthiouracil: Less commonly used due to potential liver toxicity.

    Aldosterone Analogue

    • Fludrocortisone: Mimics aldosterone, used in Addison's disease or orthostatic hypotension.

    Cation Exchange Resins

    • Bind potassium in the gut, used in hyperkalemia management.
      • Patiromer: Treatment of chronic hyperkalemia, non-absorbed.
      • Sodium Polystyrene Sulfonate: Traditional therapy for acute hyperkalemia.
      • Zirconium Cyclosilicate: Newer agent for potassium control.

    Drugs which Increase Insulin Sensitivity

    • Enhance insulin action on target tissues.
      • Metformin: First-line therapy for type 2 diabetes, reduces hepatic glucose production.
      • Pioglitazone: Thiazolidinedione, promotes adipocyte differentiation, lowers insulin resistance.

    Vasopressin (ADH) Antagonists

    • Block vasopressin receptor actions, used in conditions like hyponatremia.
      • Demeclocycline: Tetracycline antibiotic, also used for SIADH.
      • Conivaptan: Non-selective V1A/V2 receptor antagonist.
      • Tolvaptan: Selective V2 receptor antagonist; treats hyponatremia.

    Dopamine Agonists

    • Act on dopamine receptors to modulate various physiological processes.
      • Bromocriptine: Anti-diabetic effects, improves insulin sensitivity.
      • Cabergoline: Primarily for Parkinson's disease, can influence metabolic control.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Description

    This quiz covers various classes of insulin secretion stimulants, including Sulfonylureas, GLP-1 Analogues, DPP-4 Inhibitors, and SGLT2 Inhibitors. Test your knowledge on the specific drugs within each category and their mechanisms of action. Ideal for students and professionals in the field of pharmacology or endocrinology.

    More Quizzes Like This

    Use Quizgecko on...
    Browser
    Browser